SCHEMBL18338261

SCHEMBL18338261

CCN(C(=O)Cn1c(C(=O)O)cc2ccc(OC)cc21)c1cccc(C)c1

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.50
KMT2A Q03164 3/20 0.50
MAPT P10636 5/20 0.48
TP53 P04637 3/20 0.48
ALDH1A1 P00352 3/20 0.48
NPSR1 Q6W5P4 2/20 0.48
RECQL P46063 1/20 0.47
HPGD P15428 2/20 0.47
CCR9 P51686 1/20 0.47
CCR2 P41597 1/20 0.47
LMNA P02545 2/20 0.46
KDM4E B2RXH2 1/20 0.46
HSD17B10 Q99714 1/20 0.46
RXFP1 Q9HBX9 1/20 0.45
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
POLQ O75417 1/20 0.43
TNKS O95271 1/20 0.42
TNKS2 Q9H2K2 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18338142 0.91 TP53 (0.58) MEN1KMT2AMAPTTP53ALDH1A1
SCHEMBL21975561 0.89 MEN1 (0.53) MEN1KMT2AMAPTTP53ALDH1A1
SCHEMBL18345112 0.89 CCR2 (0.49) MAPTALDH1A1HPGDCCR9CCR2
SCHEMBL18338305 0.86 MEN1 (0.61) MEN1KMT2AMAPTTP53ALDH1A1
SCHEMBL18350043 0.85 MEN1 (0.51) MEN1KMT2AMAPTTP53ALDH1A1
SCHEMBL21900204 0.83 TP53 (0.42) MEN1KMT2AMAPTTP53ALDH1A1
SCHEMBL18345113 0.83 CCR2 (0.48) MEN1KMT2AMAPTTP53ALDH1A1
SCHEMBL18338219 0.82 TP53 (0.42) MEN1KMT2AMAPTTP53ALDH1A1
SCHEMBL18338221 0.82 TP53 (0.42) MEN1KMT2AMAPTTP53ALDH1A1
SCHEMBL18350042 0.79 TP53 (0.57) MEN1KMT2AMAPTTP53ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107922428-B Thienopyrrole compounds and their use as inhibitors of oplophorus-derived luciferase 普洛麦格公司 2021-02-05 CN disclosed
EP-3313846-B1 THIENOPYRROLE COMPOUNDS AND USES THEREOF AS INHIBITORS OF OPLOPHORUS-DERIVED LUCIFERASES PROMEGA CORP (US) 2020-05-06 EP disclosed
EP-3313846-B1 THIENOPYRROLE COMPOUNDS AND USES THEREOF AS INHIBITORS OF OPLOPHORUS-DERIVED LUCIFERASES PROMEGA CORP (US) 2020-05-06 EP disclosed
US-20200063110-A1 THIENOPYRROLE COMPOUNDS AND USES THEREOF PROMEGA CORPORATION 2020-02-27 US disclosed
US-20200063110-A1 THIENOPYRROLE COMPOUNDS AND USES THEREOF PROMEGA CORPORATION 2020-02-27 US disclosed
EP-3313846-A1 THIENOPYRROLE COMPOUNDS AND USES THEREOF AS INHIBITORS OF OPLOPHORUS-DERIVED LUCIFERASES Promega Corporation (US) 2018-05-02 EP disclosed
WO-2016210294-A1 THIENOPYRROLE COMPOUNDS AND USES THEREOF AS INHIBITORS OF OPLOPHORUS-DERIVED LUCIFERASES PROMEGA CORPORATION (US) 2016-12-29 WO disclosed
US-20160376568-A1 THIENOPYRROLE COMPOUNDS AND USES THEREOF JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT 2016-12-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160376568-A1 THIENOPYRROLE COMPOUNDS AND USES THEREOF THOP1, TYMP, CREBBP MEN1 2529/4885KMT2A 2923/4885MAPT 2973/4885
US-20200063110-A1 THIENOPYRROLE COMPOUNDS AND USES THEREOF THOP1, TYMP, CREBBP MEN1 2529/4885KMT2A 2923/4885MAPT 2973/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.